Product	Pharmacopeia	US DMF	EDMF	Others
Alendronate Sodium Trihydrate	USP/In-house	√	✕	✕
Almotriptan Malate	In-house	√	✕	✕
Amlodipine Besylate	USP	√	✕	✕
Aripiprazole	EP/USP/In-house	√	√	✕
Armodafinil	In-house	√	✕	✕
Cetirizine Dihydrochloride	USP/In-house	√	✕	✕
Clopidrogel Bisulfate	USP/In-house	√	✕	✕
Desloratadine	In-house	√	✕	✕
Dexlansoprazole	In-house	√	✕	✕
Dipyridamole	USP/In-house	√	✕	✕
Divalproex Sodium	USP/In-house	√	✕	✕
Duloxetine Hydrochloride	In-house	√	√	✕
Eszopiclone	In-house	√	✕	✕
Felodipine	USP / EP/BP	√	✕	✕
Gemifloxacin Mesylate	In-house	√	✕	✕
Granisetron Hydrochloride	USP/EP/BP	√	√	√
ISA (Intermediate)	In-house	√	✕	✕
Ibandronate Sodium	In-house	√	√	✕
Lansoprazole	USP	√	✕	✕
Levetiracetam	USP/In-house/EP	√	√	✕
Levofloxacin	USP	√	✕	✕
Losartan Potassium	USP/In-house	√	✕	✕
Memantine Hydrochloride	In-house	√	√	✕
Modafinil	USP / EP	√	√	√
Naratriptan Hydrochloride	USP	√	√	✕
Nisoldipine	In-house	√	✕	✕
Paliperidone	In-house/JP	√	✕	✕
Pantoprazole Sodium	USP/In-house	√	✕	✕
Paroxetine HCl	USP/In-house	√	✕	✕
Phenytoin Sodium	USP/EP/BP/In-house	√	✕	✕
Pramipexole Dihydrochloride	USP/In-house/EP	√	√	✕
Quetiapine Fumarate	USP/EP/In-house	√	✕	✕
Rabeprazole Sodium	In-house	√	✕	✕
Rasagiline Mesylate	In-house	√	√	✕
Risedronate Sodium	USP	√	✕	✕
Rivastigmine Tartrate	EP/USP/In-house	√	√	✕
Ropinirole Hydrochloride	USP/In-house	√	✕	✕
Sumatriptan Succinate	USP /EP/BP	√	√	√
Tadalafil	EP	√	✕	✕
trans-Resveratrol (Series-A)	In-house	√	✕	✕
trans-Resveratrol	In-house	√	✕	✕
Terbinafine Hydrochloride	USP / EP/BP	√	√	√
Tolterodine Tartrate	In-house	√	✕	✕
Venlafaxine Hydrochloride	EP/USP/In-house	√	√	√
Zaleplon	USP/In-house	√	✕	✕
Zolmitriptan	USP/In-house	√	✕	✕
Zolpidem tartrate	In-house	√	✕	✕

Product exploitation, including development, sales and offer for sale are performed where permissible by patent law.
This presentation is not and should not constitute as an offer for sales in territories where it is not permitted by law.